Sax, P. E., Pozniak, A., Montes, M. L., Koenig, E., DeJesus, E., Stellbrink, H., Antinori, A., Workowski, K., Slim, J., Reynes, J., Garner, W., Custodio, J., White, K., SenGupta, D., Cheng, A., & Quirk, E. (2017). coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet, 390(10107), 2073–2082. http://access.bl.uk/ark:/81055/vdc_100053363140.0x000046